Cardiovascular diseases (CVDs) are major causes of mortality and morbidity worldwide. This project aimed to identify therapeutic targets for drug discovery in cardiometabolic diseases as well as discover new approaches for treating hyperlipidaemia using an induced pluripotent stem cell based platform. This included establishing genotype-phenotype correlations in patients with hyperlipidaemia by analysing the HKU’s own mega data of single nucleotide polymorphisms (SNPs) for the Hong Kong population, and correcting certain mutations or polymorphisms to test the feasibility and specificity of targeting the mutations in certain genes. Utilising induced pluripotent stem cells (iPSCs) derived from patients with extreme cardiometabolic phenotypes allowed the researchers to investigate the effects of rare genetic variants and research how to correct these mutations using CRISPR/Cas9 technology.